Meridor K, Berookhim J, Levy Y. Low dose naloxone for pruritus in systemic sclerosis: Case series and literature review.
Medicine (Baltimore) 2022;
101:e28653. [PMID:
35089206 PMCID:
PMC8797570 DOI:
10.1097/md.0000000000028653]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 01/04/2022] [Indexed: 01/05/2023] Open
Abstract
RATIONALE
Pruritus is a common symptom in patients with systemic sclerosis and has a tremendous effect on the quality of life. Nevertheless, current therapeutic options are limited. The pathogenesis of pruritus in systemic sclerosis is not completely understood; however, opiate-mediated neurotransmission has been postulated to be involved.
PATIENT CONCERNS AND DIAGNOSIS
We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D-itch score of 22.75.
INTERVENTION AND OUTCOMES
Low-dose oral naloxone was initiated, followed by a significant improvement in the level of pruritus, reaching an average 5D-itch score of 7.5, after 6 and 12 months of treatment. None of the patients experienced side effects.
LESSONS
Low-dose naloxone plays an important role in the management of pruritus in systemic sclerosis.
Collapse